BSc (Hons), BM (Hons), MRCP, PhD
Homepage
Latest Videos
Latest Videos
Brightcove Home Latest Listing
Breast Cancer
Breast Cancer
Brightcove Cards Listing
Prostate Cancer
Brightcove Cards Listing
Multiple Myeloma
Multiple Myeloma
Brightcove Cards Listing
Popular on MedEnrich
Popular in No name
- Breast Cancer3m 2s
ESR1 Mutation as an emerging clinical biomarker metastatic hormone receptor positive Breast Cancer
Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.
- Breast Cancer14m 46s
ESMO 2022 Breast Cancer Comprehensive Coverage
View comprehensive coverage of Breast Cancer from ESMO 2022
- Myelodysplastic Syndromes8m 45s
Current Challenges in MDS Diagnosis and Consequences
Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
- Prostate Cancer7m 6s
Treating Metastatic Hormone Refractory Prostate Cancer - My Approach
Revised definition of Castration Resistant Prostate Cancer (mCRPC) considers castration range testosterone with either biochemical progression with three consecutive rises in PSA or evidence of radiological progression.
- Breast Cancer1m 21s
Recent advances in triple-negative breast cancer (TNBC)
Metastatic Triple Negative Breast Cancer is still an unmet medical need.
- OncoSpecials2m 41s
Low Dose Dasatinib Ready For Clinical Practice
Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.
- Prostate Cancer49m 18s
Dissecting the biology of advanced prostate cancer
Advanced prostate cancer is characterized by intricate biological changes, including genetic and epigenetic alterations, as well as shifts in cellular metabolism.
- Breast Cancer11m 14s
Oral Selective Estrogen Receptor Degraders for ESR-1 Mutant Metastatic Breast Cancer
Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.
- OncoSpecials7m 52s
Treatment Free Remission in CML - Ready for Prime Time
TFR strategy is generally safe with adequate monitoring. Restarting TKI after loss of Major Molecular Response is safe with 80% of patients regaining MR4 after restarting TKI treatment.
- Pharmacy37m 20s
Quality management systems in pharmacy practice
Dr Scott Soefje, PharmD, Mayo Clinic
Provides a perspective “Quality Management Systems in Pharmacy Practice”.
- 1
ESR1 Mutation as an emerging clinical biomarker...
- 2
ESMO 2022 Breast Cancer Comprehensive Coverage
- 3
Current Challenges in MDS Diagnosis and Consequences
- 4
Treating Metastatic Hormone Refractory Prostate...
- 5
Recent advances in triple-negative breast cancer...
- 6
Low Dose Dasatinib Ready For Clinical Practice
- 7
Dissecting the biology of advanced prostate cancer
- 8
Oral Selective Estrogen Receptor Degraders for...
- 9
Treatment Free Remission in CML - Ready for Prime...
- 10
Quality management systems in pharmacy practice
For Pharmacist
For Pharmacist
Brightcove Cards Listing
Webinars
Webinar Cards Listing
Upcoming Webinar
Upcoming Webinar
MedBytes
MedBytes
Medbytes Cards Listing
Notable KOLs
Discover Notable KOLs
M.D., MSCE
M.D.
M.D., MSC
M.D.
M.D.
